Veeva Systems Inc.
VEEVHealthcareNASDAQHealth Information Services · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Veeva Systems Inc. focuses on Health Information Services services and products. Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company carries a $51.52B market cap, placing it firmly in the large-cap category. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands.
Market Cap
$51.52B
Beta
0.93
P/E (TTM)
52.16
P/E (Fwd)
31.04
EPS (TTM)
$6.10
EPS (Fwd)
$10.25
ROE
14.4%
ROA
7.6%
Cash
$7.24B
Total Debt
$151.7M
Free CF
$1.26B
52W Change
7.6%
Annual Financials
Cash vs Debt
Where VEEV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VEEV finished 52.95% above its 150-day moving average ($207.12) and 54.28% above its 200-day moving average ($205.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VEEV overbought or oversold?
At the October 20, 2026 close, VEEV's RSI(14) was 74.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $7.24B in cash and $151.7M in debt, VEEV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $1.26B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 14.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.16B (2023) to $3.20B (2026), reflecting a 48% increase over the period.
With cash comfortably exceeding debt, VEEV has financial flexibility that may help navigate uncertain periods. At over 50x earnings, VEEV carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VEEV.